WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treating diabetes, comprising:

metformin; and

teneligliptin,

wherein the pharmaceutical composition comprises a separating layer to block contact between the metformin and the teneligliptin, and the separating layer is present in an amount of 2 to 5 wt% per the total weight of the pharmaceutical composition .

2. The pharmaceutical composition for treating diabetes according to claim 1, wherein the metformin is incorporated into an inner layer, the teneligliptin is incorporated into an outer layer, and the separating layer constitutes an intermediate layer interposed between the inner layer and the outer layer.

3. The pharmaceutical composition for treating diabetes according to claim 2, wherein the inner layer further comprises a swellable polymer, and the swellable polymer is at least one selected from the group consisting of hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose sodium, cross-linked carboxymethylcellulose and its derivatives, methylcellulose, ethylcellulose and its salt or derivatives, carboxy vinyl polymer, polyvinylalcohol, polyethylene oxide (PEO), polymethacrylate polymer, and pharmaceutically acceptable biodegradable cellulose derivatives.

4. The pharmaceutical composition for treating diabetes according to claim 3, wherein the swellable polymer is a polymer having viscosity of 1,000 to 200,000 centipoise (cps).

5. The pharmaceutical composition for treating diabetes according to claim 4, wherein the swellable polymer is a polymer having viscosity of 4,000 to 200,000 centipoise (cps).

6. The pharmaceutical composition for treating diabetes according to claim 3, wherein the swellable polymer is present in an amount of 20 to 50 wt% per the total weight of the pharmaceutical composition.

7. The pharmaceutical composition for treating diabetes according to claim 2, wherein the outer layer further comprises at least one release modifying agent selected from the group consisting of hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC), microcrystalline cellulose (MCC), polyvinylalcohol, methylcellulose (MC), hydroxypropylcellulose (HPC), celluloseacetate phthalate (CAP), hydroxypropylmethylcellulose phthalate (HPMCP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), and polymethacrylate polymer.

8. The pharmaceutical composition for treating diabetes according to claim 2, wherein the intermediate layer is at least one aqueous polymer selected from the group consisting of hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC), polyvinylalcohol, and hydroxypropylcellulose (HPC).

9. The pharmaceutical composition for treating diabetes according to claim 1, wherein the pharmaceutical composition for treating diabetes is for oral use.

10. The pharmaceutical composition for treating diabetes according to claim 1, wherein the metformin is present in an amount of 250 mg to 1000 mg.

11. The pharmaceutical composition for treating diabetes according to claim 1, wherein the teneligliptin is present in an amount of 25 mg to 100mg.

12. A preparation method of a pharmaceutical composition for treating diabetes, comprising:

i) preparing an inner layer comprising metformin;

ii) preparing an intermediate layer by coating a surface of the inner layer with at least one aqueous polymer selected from the group consisting of hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC), and hydroxypropylcellulose (HPC); and

iii) preparing an outer layer comprising teneligliptin on a surface of the intermediate layer.